PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27214664-0 2016 A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson"s Disease. Levodopa 84-92 glutamate receptor, ionotropic, kainate 1 Mus musculus 30-36 21161716-3 2011 Different negative allosteric modulators (NAMs) of mGluR5 were repeatedly shown to be efficacious in models of L: -DOPA-induced dyskinesia (LID), anxiety, and some forms of pain. Levodopa 111-119 glutamate receptor, ionotropic, kainate 1 Mus musculus 51-57 24865335-1 2014 BACKGROUND: Blocking metabotropic glutamate receptor type 5 (mGluR5) has been proposed as a target for levodopa-induced dyskinesias (LID) in Parkinson"s disease (PD). Levodopa 103-111 glutamate receptor, ionotropic, kainate 1 Mus musculus 61-67 24029003-0 2013 Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action. Levodopa 51-57 glutamate receptor, ionotropic, kainate 1 Mus musculus 11-17 24960254-4 2014 A potential strategy, currently under investigation, is the coadministration of metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators (NAMs) and L-DOPA; a treatment that results in the improvement of dyskinesia symptoms and that permits reductions in l-DOPA dosage frequency. Levodopa 271-277 glutamate receptor, ionotropic, kainate 1 Mus musculus 115-121 24960254-7 2014 EXPERT OPINION: Interaction between mGluR5 NAM and L-DOPA is an area of interest in PD research as concomitant treatment results in the improvement of LID symptoms in humans, thus enhancing the patient"s quality of life. Levodopa 51-57 glutamate receptor, ionotropic, kainate 1 Mus musculus 36-42 20074579-7 2010 Our results showed a beneficial antidyskinetic effect of blocking mGluR5 in L-Dopa-treated MPTP monkeys. Levodopa 76-82 glutamate receptor, ionotropic, kainate 1 Mus musculus 66-72 21484883-6 2011 We investigated the effects of the mGluR5 antagonist, 2-methyl-6-(phenylethynyl) pyridine (MPEP) on the striatal expression of VGlut1 and VGlut2 in levodopa-treated hemiparkinsonian rats. Levodopa 148-156 glutamate receptor, ionotropic, kainate 1 Mus musculus 35-41 20452425-0 2010 A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Levodopa 56-62 glutamate receptor, ionotropic, kainate 1 Mus musculus 2-8 19660528-1 2009 The present study examined the effect of a subchronic systemic administration of the glutamate metabotropic mGluR5 receptor antagonist MPEP on l-DOPA-induced dyskinesias and striatal gene expression in adult rats with a unilateral 6-OHDA lesion of dopamine neurons. Levodopa 143-149 glutamate receptor, ionotropic, kainate 1 Mus musculus 108-114 19660528-0 2009 Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats. Levodopa 159-165 glutamate receptor, ionotropic, kainate 1 Mus musculus 23-29 20132464-1 2010 Behavioral investigations of selective and potent metabotropic glutamate receptor type 5 (mGluR5) antagonists in animal models suggest involvement of mGluR5 in compensatory mechanisms of the basal ganglia circuitry in Parkinson"s disease and levodopa (L-Dopa) induced motor complications. Levodopa 242-250 glutamate receptor, ionotropic, kainate 1 Mus musculus 90-96 20132464-1 2010 Behavioral investigations of selective and potent metabotropic glutamate receptor type 5 (mGluR5) antagonists in animal models suggest involvement of mGluR5 in compensatory mechanisms of the basal ganglia circuitry in Parkinson"s disease and levodopa (L-Dopa) induced motor complications. Levodopa 252-258 glutamate receptor, ionotropic, kainate 1 Mus musculus 90-96 20132464-1 2010 Behavioral investigations of selective and potent metabotropic glutamate receptor type 5 (mGluR5) antagonists in animal models suggest involvement of mGluR5 in compensatory mechanisms of the basal ganglia circuitry in Parkinson"s disease and levodopa (L-Dopa) induced motor complications. Levodopa 252-258 glutamate receptor, ionotropic, kainate 1 Mus musculus 150-156 20132464-3 2010 The effect of a chronic 1 month treatment with L-Dopa on mGluR5-specific binding and mRNA levels was investigated in MPTP monkeys killed 4 or 24 h after their last L-Dopa administration. Levodopa 47-53 glutamate receptor, ionotropic, kainate 1 Mus musculus 57-63 20132464-6 2010 In contrast, caudate nucleus and putamen mGluR5 mRNA levels were elevated only in L-Dopa-treated MPTP monkeys killed 4 h after their last L-Dopa administration. Levodopa 82-88 glutamate receptor, ionotropic, kainate 1 Mus musculus 41-47 20132464-6 2010 In contrast, caudate nucleus and putamen mGluR5 mRNA levels were elevated only in L-Dopa-treated MPTP monkeys killed 4 h after their last L-Dopa administration. Levodopa 138-144 glutamate receptor, ionotropic, kainate 1 Mus musculus 41-47 20132464-7 2010 MPTP monkeys killed 4 h after their last L-Dopa treatment showed higher caudate nucleus and putamen L-Dopa concentrations compared with those killed after 24 h. Hence, mGluR5 in the putamen are sensitive to presence of L-Dopa leading to a rapid decrease of [(3)H]ABP688-specific binding possibly involving a direct mGluR5/dopamine receptors interaction. Levodopa 41-47 glutamate receptor, ionotropic, kainate 1 Mus musculus 168-174 20132464-7 2010 MPTP monkeys killed 4 h after their last L-Dopa treatment showed higher caudate nucleus and putamen L-Dopa concentrations compared with those killed after 24 h. Hence, mGluR5 in the putamen are sensitive to presence of L-Dopa leading to a rapid decrease of [(3)H]ABP688-specific binding possibly involving a direct mGluR5/dopamine receptors interaction. Levodopa 100-106 glutamate receptor, ionotropic, kainate 1 Mus musculus 168-174 20132464-7 2010 MPTP monkeys killed 4 h after their last L-Dopa treatment showed higher caudate nucleus and putamen L-Dopa concentrations compared with those killed after 24 h. Hence, mGluR5 in the putamen are sensitive to presence of L-Dopa leading to a rapid decrease of [(3)H]ABP688-specific binding possibly involving a direct mGluR5/dopamine receptors interaction. Levodopa 100-106 glutamate receptor, ionotropic, kainate 1 Mus musculus 168-174 19660528-8 2009 Altogether, the findings support the idea that the relative efficacy of mGluR5 receptor antagonists to oppose l-DOPA-induced abnormal involuntary movements involves an ability to oppose increases in GAD gene expression and GABA-mediated signaling in striatonigral and striatopallidal neurons. Levodopa 110-116 glutamate receptor, ionotropic, kainate 1 Mus musculus 72-78 19660528-9 2009 The results also confirm the potential usefulness of antagonists of mGluR5 receptors as adjuncts in the treatment of l-DOPA-induced dyskinesia in patients with Parkinson"s disease. Levodopa 117-123 glutamate receptor, ionotropic, kainate 1 Mus musculus 68-74 18690408-0 2008 Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats. Levodopa 108-116 glutamate receptor, ionotropic, kainate 1 Mus musculus 65-71 17359492-2 2007 In this study, we addressed the role of mGluR5 in l-DOPA-induced dyskinesia, a movement disorder that is due to abnormal activation of both dopamine and glutamate receptors in the basal ganglia. Levodopa 50-56 glutamate receptor, ionotropic, kainate 1 Mus musculus 40-46 17353071-2 2008 In this study receptor binding autoradiography of [3H]MPEP, a metabotropic glutamate receptor 5 (mGluR5) selective radioligand, was used to investigate possible changes in mGluR5 in the basal ganglia of l-Dopa-treated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys having developed LIDs compared to animals in which LIDs was prevented by adjunct treatments. Levodopa 203-209 glutamate receptor, ionotropic, kainate 1 Mus musculus 172-178 17933546-0 2008 Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson"s disease. Levodopa 100-106 glutamate receptor, ionotropic, kainate 1 Mus musculus 30-36 17933546-6 2008 Our data confirm the role of glutamatergic neurotransmission in the pathogenesis of dyskinesias and the potential of mGluR5 antagonists in the treatment of l-DOPA-induced dyskinesias. Levodopa 156-162 glutamate receptor, ionotropic, kainate 1 Mus musculus 117-123 17359492-8 2007 These data demonstrate that mGluR5 antagonism produces strong anti-dyskinetic effects in an animal model of Parkinson"s disease through central inhibition of the molecular and neurochemical underpinnings of l-DOPA-induced dyskinesia. Levodopa 207-213 glutamate receptor, ionotropic, kainate 1 Mus musculus 28-34 16564428-9 2006 However, mGluR5 antagonists may prove useful for the symptomatic treatment of L-DOPA-induced dyskinesia. Levodopa 78-84 glutamate receptor, ionotropic, kainate 1 Mus musculus 9-15 31422483-1 2019 Preclinical evidence indicates that mGluR5 is a potential therapeutic target for Parkinson"s disease and L-DOPA-induced dyskinesia. Levodopa 105-111 glutamate receptor, ionotropic, kainate 1 Mus musculus 36-42 30439288-0 2018 L-DOPA-Induced Motor Impairment and Overexpression of Corticostriatal Synaptic Components Are Improved by the mGluR5 Antagonist MPEP in 6-OHDA-Lesioned Rats. Levodopa 0-6 glutamate receptor, ionotropic, kainate 1 Mus musculus 110-116 30259400-0 2019 Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates L-DOPA-Induced Dyskinesia in Aphakia Mice. Levodopa 74-80 glutamate receptor, ionotropic, kainate 1 Mus musculus 21-27 30259400-10 2019 Downregulating mGluR5 or nicotine treatment after L-DOPA decreased ERK and histone 3 activation, and FosB expression. Levodopa 50-56 glutamate receptor, ionotropic, kainate 1 Mus musculus 15-21 30271338-0 2018 Effects of mGluR5 Antagonists on Parkinson"s Patients With L-Dopa-Induced Dyskinesia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Levodopa 59-65 glutamate receptor, ionotropic, kainate 1 Mus musculus 11-17 30271338-1 2018 Background: Modulation of Metabotropic glutamate receptor 5 (mGluR5) may be a novel therapeutic approach to manage Parkinson"s disease (PD) Patients with L-dopa-induced dyskinesia (LID). Levodopa 154-160 glutamate receptor, ionotropic, kainate 1 Mus musculus 61-67 29055799-0 2018 Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson"s disease and levodopa-induced dyskinesia. Levodopa 118-126 glutamate receptor, ionotropic, kainate 1 Mus musculus 8-14 29055799-1 2018 Several lines of evidence point to alterations in glutamatergic signaling in Parkinson"s disease (PD) and levodopa-induced dyskinesia (LID), involving the metabotropic glutamate receptor type 5 (mGluR5). Levodopa 106-114 glutamate receptor, ionotropic, kainate 1 Mus musculus 195-201 29055799-6 2018 However, following L-DOPA, an increase in relative mGluR5 uptake was present in the contralateral motor cortex and somatosensory cortex. Levodopa 19-25 glutamate receptor, ionotropic, kainate 1 Mus musculus 51-57 29055799-9 2018 Relative mGluR5 uptake in the CP of levodopa-treated rats was also found positively correlated with abnormal involuntary movement scores. Levodopa 36-44 glutamate receptor, ionotropic, kainate 1 Mus musculus 9-15